Vignettes in Kinase Inhibitor Drug Discovery: Evolution of a Drug Target Class

Seminar series
Organic Colloquium
Thu, Mar 7 5:00pm
Cram Conference Room - 3440 Mol Sci
Speaker Dr. Joel C. Barrish
Vice President of Medicinal Chemistry
Bristol-Myers Squibb Co.

Abstract.  Protein kinases are critical players in intracellular signal transduction pathways and the etiology of many human diseases.  Over the last three decades, our understanding of this biological target class has grown such that there are now over 15 kinase inhibitors on the market for the treatment of cancer.  This presentation will describe the evolution of kinase drug discovery and development using three clinical candidate case histories to highlight key past milestones and future challenges.